FANFT

07/01/1982 - "In this present study, BCG treatment promoted rather than inhibited the growth of FANFT tumor. "
08/21/1998 - "FANFT cells are protected from direct cell kill mediated by this drug, suggesting that the substantial delay in tumor regrowth from this tumor/sensitizer combination can be attributed to vascular effects."
07/01/1993 - "Using a standard clonogenic assay and the AY-27 FANFT tumor line, photoactivation of CDS1 was shown to be cytotoxic. "
10/01/1987 - "Urinary tract tumors were not found in rats treated with FANFT or E. "
01/01/1987 - "Neither amplification nor gross rearrangements were detected by Southern analysis in the FANFT tumor. "

04/01/1979 - "Intercellular junctions in FANFT-induced carcinomas of rat urinary bladder in tissue culture: in situ thin-section, freeze-fracture, and scanning electron microscopy studies."
10/01/1991 - "The results showed no mutation within the examined DNA sequences, indicating that neu oncogene is not activated by a point mutation in the transmembrane domain in urinary bladder carcinomas induced by BBN, FANFT or MNU."
12/01/1986 - "SS in the AIN-76A diet increased the incidence of bladder carcinoma in the rats which had been treated with FANFT or DBN, but the increase was not significant (P = 0.059 and 0.327, respectively). "
03/01/1984 - "It is proposed that the use of the Nb rat be utilized to develop a data base to advance understanding of the management of bladder carcinoma induced by FANFT ingestion in Nb rats. "
01/01/1984 - "0.2% FANFT followed by control diet induced bladder carcinomas in 18 of 21 (87%) rats, but when ASA was co-administered, only 10 of 27 (37%) rats developed bladder carcinoma (p less than 0.001). "

02/15/1990 - "twice a week for 14 weeks starting on day 30 of start of FANFT feeding developed fewer transitional cell carcinomas (TCC) than mice treated with the vehicle. "
01/01/1987 - "Enhanced expression of Harvey-ras oncogene in FANFT-induced transitional cell carcinoma."
12/01/1986 - "PB significantly increased the incidence of transitional cell carcinoma of the bladder of the rats that had been treated with FANFT (P = 0.027). "
01/01/1986 - "Four sublines of a murine N-[4-(5-nitro-2-furyl)-2-thiazolyl]-foramide (FANFT)-induced transitional cell carcinoma (MBT-2) possessing spontaneous metastatic ability were isolated via in vivo/in vitro serial selection of metastatic lung lesions. "
03/01/1985 - "In contrast to the preneoplastic lesions, FANFT-induced transitional cell carcinoma showed differential staining within the tumors. "

03/01/1984 - "This laboratory unit has been working with the Nb rat prostate adenocarcinoma model for the last several years and has recently used this model system to study efficacy of various chemotherapeutic agents in FANFT-induced bladder carcinomas in this rat strain. "
05/01/1981 - "However, the number of animals with one or more adenocarcinomas of the bowel (22/30 vs. 17/50, P less than 0.001), the mean number of tumors per animal (2.1 +/- 0.2 vs. 1.1 +/- 0.1, P less than 0.01), and the invasiveness of the tumors were all increased after DMH + FANFT as compared with DMH exposure alone. "
02/01/1980 - "However, the number of animals with one or more adenocarcinomas of the bowel (22/30 versus 17/50, p < 0.001), the mean number of tumors per animal (2.1 +/- 0.2 versus 1.1 +/- 0.1, p < 0.01), and the invasiveness of the tumors through the bowel wall were all significantly increased after DMH + FANFT compared to DMH exposure alone."
02/01/1980 - "Adenocarcinomas of the large and small bowel occurred in approximately 33% of DMH-treated animals, and transitional cell carcinomas of the urinary bladder in approximately 33% of the FANFT-treated animals. "
05/01/1981 - "In unoperated or sham operated animals, adenocarcinomas of the bowel occurred in 33% of DMH-treated animals and transitional cell carcinomas of the urinary bladder in 33% of the FANFT-treated animals. "

01/01/1984 - "The incidences of mammary fibroadenoma in the NF group and of lower urinary tract tumors in the FANFT group were significantly greater (P less than 0.01) than those of these tumors in the control group."